Q-omics provides the consensus-scored STON1-GTF2A1L profile across patient tissues and cancer cell-line models. STON1-GTF2A1L expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, STON1-GTF2A1L is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, STON1-GTF2A1L RNA expression shows 9,391 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight ACC, KICH, and UCEC as cancer lineages where STON1-GTF2A1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STON1-GTF2A1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STON1-GTF2A1L survival associations across molecular data types. STON1-GTF2A1L RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STON1-GTF2A1L RNA expression–survival associations across cancer types. High STON1-GTF2A1L expression shows unfavorable associations in ACC, BRCA, READ and UCEC, but favorable associations in HNSC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for STON1-GTF2A1L RNA expression.
This table summarizes STON1-GTF2A1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for STON1-GTF2A1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STON1-GTF2A1L shows lower tumor expression in KICH, BLCA, THCA, UCEC, STAD and BRCA. The KICH box plot shows higher STON1-GTF2A1L RNA expression in normal versus tumor tissue (log2 FC = −0.219, t-test p < 0.001).
This table shows molecular features associated with STON1-GTF2A1L in patient tissues and cancer cell lines. In patient samples, STON1-GTF2A1L shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, STON1-GTF2A1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
